Aung Naing

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors
    Aung Naing
    1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston Texas, USA
    J Cancer 2:81-9. 2011
  2. pmc Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 32:154-9. 2014
  3. doi request reprint A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies
    Aung Naing
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Invest New Drugs 31:967-73. 2013
  4. pmc Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs
    A Naing
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 23:2960-3. 2012
  5. pmc Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
    A Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 108:826-30. 2013
  6. pmc Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
    A Naing
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 107:1093-9. 2012
  7. pmc Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2625-31. 2012
  8. doi request reprint Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase 1 Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:5142-50. 2011
  9. doi request reprint A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors
    Aung Naing
    Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, Unit 455, University of Texas MD Anderson Cancer Center, Houston, TX 77030 1402, USA
    Invest New Drugs 30:327-34. 2012
  10. pmc Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
    Clin Cancer Res 17:6052-60. 2011

Detail Information

Publications76

  1. pmc Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors
    Aung Naing
    1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston Texas, USA
    J Cancer 2:81-9. 2011
    ..Conclusions: SSG in combination with IFN-α 2b was well tolerated and augmented cellular immune parameters...
  2. pmc Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 32:154-9. 2014
    ..TAS-106 was designed to inhibit RNA synthesis by blocking RNA polymerases I, II, and III...
  3. doi request reprint A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies
    Aung Naing
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Invest New Drugs 31:967-73. 2013
    ....
  4. pmc Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs
    A Naing
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 23:2960-3. 2012
    ..Prolongation of the corrected QT interval (QTc) by noncardiac drugs is the most common cause of drug development delays, nonapprovals and postmarketing withdrawals by the US Food and Drug Administration...
  5. pmc Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
    A Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 108:826-30. 2013
    ..Cixutumumab, a fully human IgG1 monoclonal antibody directed at IGF-1R was combined with temsirolimus on the basis of preclinical data...
  6. pmc Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
    A Naing
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 107:1093-9. 2012
    ..This study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of the first-in-class dual mammalian target of rapamycin complex (mTORC)1/mTORC2 inhibitor, AZD8055...
  7. pmc Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2625-31. 2012
    ..Temsirolimus was combined with cixutumumab, a fully human IgG1 monoclonal antibody directed at the insulin growth factor-1 receptor (IGF-1R)...
  8. doi request reprint Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase 1 Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:5142-50. 2011
    ..Therefore, the concurrent use of complementary and alternative medicine (CAM) in patients with advanced malignancies seen in a dedicated phase 1 clinic was evaluated...
  9. doi request reprint A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors
    Aung Naing
    Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, Unit 455, University of Texas MD Anderson Cancer Center, Houston, TX 77030 1402, USA
    Invest New Drugs 30:327-34. 2012
    ....
  10. pmc Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
    Clin Cancer Res 17:6052-60. 2011
    ..The objectives of this phase I study were to evaluate the tolerability and activity of temsirolimus and cixutumumab...
  11. pmc PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012
    ..PIK3CA mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/AKT/mTOR pathway inhibitors...
  12. doi request reprint Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity
    John Moroney
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:5796-805. 2012
    ..Preclinical data suggest that combining the mTOR/hypoxia-inducible factor (HIF) inhibitor temsirolimus and the antiangiogenesis antibody bevacizumab may augment antitumor activity as well as resensitize cells to anthracyclines...
  13. pmc Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
    Ishwaria M Subbiah
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:153-62. 2013
    ..Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease...
  14. doi request reprint Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1422-8. 2012
    ....
  15. ncbi request reprint Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
    Prasanth Ganesan
    Corresponding Author Filip Janku, Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8 2018, Box 0455, Houston, Texas 77030
    Mol Cancer Ther 12:2857-63. 2013
    ..PIK3CA mutations are associated with simultaneous KRAS mutations, possibly accounting for therapeutic resistance...
  16. ncbi request reprint Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer
    Prasanth Ganesan
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 31:1505-13. 2013
    ..Lenalidomide, an immunomodulatory and anti-angiogenic drug, and temsirolimus, an mTOR inhibitor, have synergistic anti-cancer effects in preclinical models. We conducted a phase I study of the combination in patients with advanced cancers...
  17. pmc Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Texas, USA
    Oncotarget 4:772-84. 2013
    ..We therefore investigated the outcome of EGFR inhibitor-based combination regimens in patients with heavily-pretreated non-small cell lung cancer (NSCLC) referred to a Phase I Clinic...
  18. doi request reprint Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6373-83. 2012
    ..We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations...
  19. doi request reprint A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Invest New Drugs 31:918-26. 2013
    ..Dasatinib has been shown preclinically to overcome resistance to gemcitabine. We evaluated the safety and biological activity of the combination of dasatinib and gemcitabine in patients with advanced solid tumors...
  20. pmc KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e38033. 2012
    ..To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents...
  21. pmc Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 16:327-35. 2011
    ..The outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated in phase I clinical trials have not been systematically analyzed...
  22. pmc Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:997-1005. 2011
    ..We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras and other farnesylated proteins...
  23. ncbi request reprint Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Colorectal Cancer 11:297-303. 2012
    ..Patients with advanced colorectal cancer have a poor prognosis once standard therapies fail. This retrospective study presents the characteristics and outcomes in 144 patients treated in phase I clinical trials...
  24. pmc PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:276-84. 2013
    ..6, 95% confidence interval (CI), 1.02-43.0, P = 0.047). Our data suggest that interaction between PIK3CA mutation H1047R versus other aberrations and response to PI3K/AKT/mTOR axis inhibitors warrants further exploration...
  25. doi request reprint Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 71:389-97. 2013
    ..Liver metastases in patients with cancer are associated with poor survival. We hypothesized that hepatic arterial infusion (HAI) of oxaliplatin combination therapy would have antitumor activity in these patients...
  26. pmc Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 66:1087-93. 2010
    ..We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement...
  27. pmc A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies
    John W Moroney
    Department of Gynecology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:6840-6. 2011
    ..We, therefore, added temsirolimus (T), which inhibits HIF-1α, to D and A (DAT). Trial objectives were assessment of safety, preliminary efficacy, and identification of biological response correlates...
  28. pmc Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:247-53. 2011
    ..The survival of patients with liver metastases from solid tumors is poor. We conducted a phase I study of hepatic arterial infusion (HAI) paclitaxel in patients with advanced cancer and predominant liver involvement...
  29. pmc PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22769. 2011
    ..Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis...
  30. ncbi request reprint Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations
    Jennifer J Wheler
    Corresponding Author Jennifer Wheler, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1400 Holcombe Boulevard, Houston, TX 77030
    Mol Cancer Ther 12:2167-75. 2013
    ..This combination warrants further study in select populations of non-small cell lung cancer...
  31. doi request reprint A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas
    David S Hong
    Department ofInvestigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:3396-406. 2012
    ....
  32. ncbi request reprint Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Biostatistics, and Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2922-9. 2012
    ....
  33. ncbi request reprint MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
    David S Hong
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston TX, USA Electronic address
    Lancet Oncol 15:656-66. 2014
    ..We aimed to assess the safety and tolerability of MABp1 for interleukin-1α blockade in a refractory cancer population...
  34. ncbi request reprint Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 73:495-501. 2014
    ..We conducted a phase I study of the combination of the anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers...
  35. doi request reprint A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer
    Stacy Moulder
    Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Unit 1354, 1155 Pressler Street, Houston, TX 77030, USA
    Invest New Drugs 28:634-40. 2010
    ..This trial was designed to establish the maximum tolerated dose (MTD) of imexon given with docetaxel in breast, prostate and non-small cell lung cancer (NSCLC)...
  36. pmc P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
    Rabin Said
    Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:705-14. 2013
    ..Mutations in the p53 gene are amongst the most frequent aberrations seen in human cancer. Our objective was to characterize the clinical characteristics associated with p53 mutation in patients with advanced cancer...
  37. pmc PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    Filip Janku
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:777-82. 2012
    ..Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance...
  38. pmc Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit
    Siqing Fu
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncologist 18:1315-20. 2013
    ..We conducted this retrospective study to identify reasons that patients referred to a phase I clinical trial failed to enroll or delayed enrollment onto the trial...
  39. ncbi request reprint Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:3029-38. 2014
    ..Since PI3K/AKT/mTOR pathway activation diminishes the effects of hormone therapy, combining aromatase inhibitors (anatrozole) with mTOR inhibitors (everolimus) was investigated...
  40. pmc Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics A Phase I Clinical Trials Program, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:890-8. 2013
    ..Thymomas and thymic carcinoma are rare tumors with no approved therapies. Our purpose was to analyze the molecular features and outcomes of patients referred to the Clinical Center for Targeted Therapy (Phase I Clinic)...
  41. pmc Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
    Sarina A Piha-Paul
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:1846-55. 2014
    ..Temsirolimus attenuates upregulation of HIF-1α levels, a resistance mechanism for antiangiogenics, and targets the PI3-kinase/AKT/mTOR axis, commonly aberrant in these tumors...
  42. ncbi request reprint Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 32:465-72. 2014
    ..Preclinical data showed that trientine, a copper-lowering agent, re-sensitized cancer cells to carboplatin through enhanced human copper transporter 1 (hCtr1) -mediated platinum uptake...
  43. pmc Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial
    Ana M Gonzalez-Angulo
    Authors Affiliations Departments of Breast Medical Oncology and Systems Biology, Surgical Oncology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas Sarcoma Oncology Center, Santa Monica Division of Hematology Oncology, University of California, San Diego, California and Celgene, Summit, New Jersey
    Clin Cancer Res 19:5474-84. 2013
    ..This dose-finding phase I study investigated the maximum-tolerated dose (MTD) and safety of weekly nanoparticle albumin-bound rapamycin (nab-rapamycin) in patients with untreatable advanced nonhematologic malignancies...
  44. pmc Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 31:1192-200. 2013
    ..Clinical correlates included evaluation of epigenetic changes, methylation patterns, and histone acetylation levels in peripheral blood mononuclear cells...
  45. doi request reprint Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer
    Prasanth Ganesan
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 32:279-86. 2014
    ..We conducted a Phase I study of lenalidomide and sorafenib in patients with advanced cancer...
  46. ncbi request reprint Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA Electronic address
    Cell Rep 6:377-87. 2014
    ..This work provides further important clinical validation for continued and accelerated use of biomarker-driven trials incorporating rational drug combinations...
  47. pmc A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 71:955-63. 2013
    ..We conducted a phase I clinical trial for patients with advanced cancer and predominant liver disease...
  48. ncbi request reprint Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 30:2891-6. 2012
    ..Patients with advanced malignancies referred for early clinical trials have a short life expectancy. We designed this survey to ascertain the status of advance care planning in this population...
  49. pmc Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience
    Christos Vaklavas
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 117:77-85. 2011
    ..The purpose of this study was to report the presenting characteristics and outcomes of patients with locally advanced or metastatic pancreatic cancer treated on phase 1 clinical trials at a single institution...
  50. ncbi request reprint Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program
    Ming Mo Hou
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, U S A
    Anticancer Res 34:2349-55. 2014
    ..We evaluated clinical outcomes of patients with metastatic cervical cancer referred to a Phase I Clinical Trials Program...
  51. ncbi request reprint Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 120:2164-73. 2014
    ..The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF) pathway with combined bevacizumab and cediranib (a VEGF receptor tyrosine kinase inhibitor)...
  52. pmc Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors
    David Hong
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 19:4824-31. 2013
    ..We conducted a phase I dose-finding and pharmacokinetic/pharmacodynamic study of BIIB028, a prodrug designed to inhibit Hsp90 activity...
  53. ncbi request reprint Retreatment after secondary resistance or mixed response: a pilot study
    Aung Naing
    The University of Texas, MD Anderson Cancer Center, Houston, Tex
    Oncology 85:350-5. 2013
    ..Here, we report our findings in a pilot study in patients rechallenged with agents previously producing prolonged stable disease (SD), partial or complete remission (PR/CR) or a mixed response, followed by progression...
  54. ncbi request reprint Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer
    Apostolia M Tsimberidou
    From the aDepartment of Investigational Cancer Therapeutics, and bDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Natl Compr Canc Netw 12:194-203. 2014
    ..This regimen of bendamustine (100 mg/m(2)) and bevacizumab (10 mg/kg) was well tolerated and yielded disease stabilization in selected heavily pretreated patients with advanced cancer. ..
  55. doi request reprint Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center UTMDACC, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Eur J Endocrinol 169:891-9. 2013
    ..Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Herein, we describe the clinical features and outcomes for a large series of ACC patients...
  56. ncbi request reprint Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:3547-52. 2011
    ..This study assessed outcomes of individuals with advanced cancer who required admission to an intensive care unit (ICU) after referral for an early clinical trial because they did not respond to conventional therapy...
  57. pmc BRAF mutations in advanced cancers: clinical characteristics and outcomes
    Hazem El-Osta
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e25806. 2011
    ..We examined the clinical characteristics and outcomes of patients with mutant (mut) BRAF advanced cancer referred to phase 1 clinic...
  58. pmc Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience
    Hazem El-Osta
    Department of Investigational Therapeutics, Phase 1 Program Unit 455, Division of Cancer Medicine, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 16:1292-8. 2011
    ..Research biopsies are crucial for exploring the impact of novel agents on putative targets. The current study assesses the safety and success rate associated with performing such biopsies...
  59. doi request reprint Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Breast Cancer 10:46-51. 2010
    ..Patients with metastatic breast cancer (MBC) refractory to standard therapy have a poor prognosis. We assessed prognostic factors and clinical outcomes for patients with MBC referred to a phase I clinic focused primarily on targeted agents...
  60. pmc Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience
    Apostolia Maria Tsimberidou
    Investigational Cancer Therapeutics and Quantitative Sciences Division, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 17:4110-8. 2011
    ..Patients with brain metastases are often excluded from clinical trials, but it is unclear whether they pose an enhanced risk...
  61. doi request reprint Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 10:1300-7. 2011
    ..HAI nab-paclitaxel showed partial hepatic extraction. At doses 260 mg/m(2) or less given for 1 hour every 3 weeks, the treatment was well-tolerated and showed activity in advanced cancer patients with predominant liver metastases...
  62. pmc FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
    Denis L Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e89388. 2014
    ..Preclinical data suggest that FBXW7 mutations sensitize cells to mTOR inhibitors. Clinicopathologic characteristics of cancer patients with FBXW7 mutations and their responses to mTOR inhibitors remain unknown...
  63. pmc Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics Phase I Program, U T MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:118-27. 2013
    ..Preclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models...
  64. doi request reprint Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis
    Apostolia M Tsimberidou
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Hepatogastroenterology 59:960-4. 2012
    ..We conducted a phase I trial of IP oxaliplatin and paclitaxel with IV paclitaxel and bevacizumab in patients with peritoneal carcinomatosis...
  65. doi request reprint A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
    David S Hong
    Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:6582-91. 2011
    ..This phase I study sought an appropriate LY2275796 dose in patients with advanced tumors...
  66. pmc Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse
    Rajul K Jain
    Department of Investigational Cancer Therapeutics, Phase I Program, MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 16:1289-97. 2010
    ..However, a substantial portion of oncology trials now investigate targeted agents, which may have different dose-response relationships than cytotoxic chemotherapies...
  67. pmc Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience
    John Moroney
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Gynecol Oncol 117:467-72. 2010
    ..Recently, rationally developed, targeted agents are entering the early clinical trials setting. We assessed patients with metastatic gynecologic cancers in a dedicated phase I clinical trials clinic in order to determine their outcome...
  68. pmc PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, FC8 2057, Box 0455, Houston, TX 77030, USA
    Mol Cancer Ther 10:558-65. 2011
    ..5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations...
  69. pmc Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies
    David S Hong
    Division of Cancer Medicine, Department of Investigational Therapeutics Phase 1 Program, Unit 455, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 15:7061-8. 2009
    ....
  70. ncbi request reprint Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, University of Texas M D Anderson Cancer Center, 1515Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:4031-7. 2010
    ....
  71. pmc Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications
    Yunyun Jiang
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:884-9. 2013
    ..Our pilot data suggest that PTPRD germline mutations may play a role in the development of Ewing sarcoma, a disease of young people, and their presence may have implications for therapy. ..
  72. pmc Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:4423-32. 2009
    ..Thyroid cancer is the most common endocrine malignancy. The outcomes of patients with relapsed thyroid cancer treated on early-phase clinical trials have not been systematically analyzed...
  73. pmc Overcoming platinum resistance through the use of a copper-lowering agent
    Siqing Fu
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 11:1221-5. 2012
    ..Evaluation of this novel strategy is warranted in larger studies to assess the efficacy of this approach for treating platinum-resistant advanced epithelial ovarian cancer in patients with high copper levels...
  74. pmc Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures
    Vivek Subbiah
    Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 6:e18424. 2011
    ..We performed morphoproteomic profiling to better understand response/resistance mechanisms of Ewing's sarcoma to IGF1R inhibitor-based therapy...
  75. ncbi request reprint Chemotherapy resistance and retreatment: a dogma revisited
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston
    Clin Colorectal Cancer 9:E1-4. 2010
    ..Herein, we report several cases in which retreatment with drugs that had failed earlier in the disease trajectory caused renewed tumor regression. The possible biologic underpinnings that might explain this phenomenon are discussed...
  76. ncbi request reprint Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics a Phase 1 Program, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer 115:1091-9. 2009
    ....